Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 24, Issue 8, 1999, Pages 823-830

  Remberger, M ^a   Svahn, B M ^a   Hentschke, P ^a   Lofgren C ^a   Ringden O ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

ATG; Cytokines; GVHD; HSCT; OKT 3; Relapse

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 6; METHOTREXATE; OKT 3; PREDNISONE; T LYMPHOCYTE ANTIBODY; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LYMPHOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CAPILLARY LEAK SYNDROME; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG INFUSION; DYSPNEA; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RESPIRATORY TRACT DISEASE; SURVIVAL; TACHYPNEA; THORAX PAIN;

EID: 0032758059     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701991     Document Type: Article

References (41)

1. Hansen J, Clift R, Thomas E et al. Transplantation of marrow from an unrelated donor to a patient with acute leukaemia. New Engl J Med 1980; 303: 565-567.
2. Ringdén O. Bone marrow transplantation using unrelated donors for hematological malignancies. Med Oncol 1997; 14: 11-22.
3. Beatty P, Hansen J, Longton G et al. Marrow transplantation from HLA-matched unrelated donors for treatment of haematological malignancies. Transplantation 1991; 51: 443-447.
4. Hows J, Bradley B, Gore S et al. Prospective evaluation of unrelated donor bone marrow transplantation. Bone Marrow Transplant 1993; 12: 371-380.
5. Nademanee A, Schmidt G, Parker P et al. The outcome of matched unrelated donor bone marrow transplantation in patients with haematological malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate and prednisolone. Blood 1995; 86: 1228-1234.
6. Ringdén O, Remberger M, Persson U et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995; 15: 619-625.
7. Speiser D, Tiercy J-M, Rufer N et al. High resolution HLA matching associated with decreased mortality after unrelated bone marrow transplantation. Blood 1996; 87: 4455-4462.
8. Oakhill A, Pamphilon D, Potter M et al. Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission. Br J Haematol 1996; 94: 574-578.
9. Carlsson B, Wallin J, Böhme J, Möller E. HLA-DR-DQ haplotypes defined by restriction fragment analysis. Correlation to serology. Hum Immunol 1987; 20: 95-113.
10. Olerup O, Zetterqvist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours. An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39: 225-235.
11. Ringdén O, Potter M, Oakhill A et al. Transplantation of peripheral blood progenitor cells from unrelated donors. Bone Marrow Transplant 1996; 17 (Suppl. 2): 62-64.
12. Shaw P, Hugh-Jones K, Hobbs J et al. Busulphan and cyclophosphamide cause little toxicity during displacement bone marrow transplantation in fifty children. Bone Marrow Transplant 1986; 1: 193-200.
13. Ringdén O, Remberger M, Carlens S et al. Low incidence of acute graft-versus-host disease, using unrelated HLA-A, -B and -DR compatible donors and conditioning, including anti-T-cell antibodies. Transplantation 1998; 66: 620-625.
14. Storb R, Deeg H, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukaemia. New Engl J Med 1986; 314: 729-735.
15. Ringdén O, Pihlstedt P, Markling L et al. Prevention of graft-versus-host disease with T-cell depletion or cyclosporine and methotrexate. A randomized trial in adult leukemic marrow recipients. Bone Marrow Transplant 1991; 7: 221-226.
16. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
17. Aschan J. Treatment of moderate to severe acute graft-versus-host disease: a retrospective analysis. Bone Marrow Transplant 1994; 14: 601-605.
18. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus host syndrome in man: a clinicopathological study of 20 long-term Seattle patients. Am J Med 1980; 69: 204-217.
19. Ljungman P, Plotkin S. Definition, clinical severity scores, and new syndromes. Scand J Infect Dis 1995; 99 (Suppl.): 87-88.
20. Ljungman P, Loré K, Aschan J et al. Use of semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive anti-viral therapy in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1996; 17: 583-587.
21. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
22. Kalbfleisch J, Prentice R. The Statistical Analysis of Failure Time Data. John Wiley and Sons: New York, 1980.
23. Breslow N, Day N, Davis W. In: Statistical Methods in Cancer Research. Vol. 1 The analysis of case-control studies. IARC Sci Publ: Lyon, 1980, pp 5-338.
24. Cox D. Regression models and life tables. J Stat Soc (B) 1972; 34: 187.
25. Hägglund H, Ringdén O, Remberger M et al. Faster neutrophil and platelet engraftment, but no difference in acute GVHD or survival, using peripheral blood stem cells from related and unrelated donors, compared to bone marrow. Bone Marrow Transplant 1998; 22: 131-136.
26. Schriber J, Chao N, Long G et al. Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation. Blood 1994; 84: 1680-1684.
27. Appelbaum F. Allogeneic bone marrow transplantation and the use of haematopoietic growth factors. Stem Cell 1995; 13: 344-350.
28. Hägglund H, Boström L, Remberger M et al. Risk factors for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplant recipients. Bone Marrow Transplant 1995; 16: 747-753.
29. Holler E, Kolb H, Möller A et al. Increased levels of TNFα precede major complications of bone marrow transplantation. Blood 1990; 75: 1011-1016.
30. Ferrara J. Cytokine dysregulation as a mechanism of graft-versus-host disease. Curr Opin Immunol 1993; 5: 794-799.
31. Antin J, Ferrara J. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964-2968.
32. Jadus M, Wepisc H. The role of cytokines in graft-versus-host reaction and disease. Bone Marrow Transplant 1992; 10: 1-14.
33. Remberger M, Ringdén O, Markling L. TNFα levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD. Bone Marrow Transplant 1995; 15: 99-104.
34. Remberger M, Ringdén O. Serum levels of cytokines after bone marrow transplantation; increased IL-8 levels during veno-occlusive disease of the liver. Eur J Haematol 1997; 59: 254-262.
35. Chatenoud L, Ferran C, Legendre C et al. In vivo cell activation following OKT3 administration. Transplantation 1990; 49: 697-702.
36. Boström L, Ringdén O, Gratama J et al. A role of herpes virus serology for the development of acute graft-versus-host disease. Bone Marrow Transplant 1990; 5: 321-326.
37. Holler E, Kolb H, Mittermuller J et al. Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumour necrosis factor alpha (TNF alpha) release in the course of pre-transplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Blood 1995; 86: 890-899.
38. Herve P, Flesch M, Tiberghien P et al. Phase I-II trial of a monoclonal anti-tumour necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 1992; 79: 3362-3368.
39. Shimozato T, Iwata M, Kawada H, Tamura N. Human immunoglobulin preparation for intravenous use induces elevation of cellular cyclic adenosine 3′:5′-monophosphate levels, resulting in suppression of tumour necrosis factor alpha and interleukin-1 production. Immunology 1991; 72: 497-503.
40. Goldman JM, Gale RP, Horowitz MM et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk of relapse associated with T-cell depletion. Ann Int Med 1988; 108: 806-814.
41. Aschan J, Ringdén O, Sundberg B et al. Increased risk of relapse in patients with chronic myelogenous leukemia given T-cell depleted marrow compared to methotrexate combined with cyclosporin or monotherapy for the prevention of graft-versus-host disease. Eur J Hematol 1993; 50: 269-274.